Health ❯ Healthcare ❯ Clinical Trials ❯ Randomized Controlled Trials

Efficacy Studies

Meta-Analysis Finds Tirzepatide Produces Largest Average Weight Loss Among FDA‑Approved GLP‑1s

Linked to dual GLP‑1/GIP targeting, tirzepatide showed larger average weight loss in trials with uncertain post‑treatment durability.

Shankh Blowing Trial Delivers Promising Sleep Apnoea Outcomes